Clinical Trials Directory

Trials / Sponsors / Diwakar Davar

Diwakar Davar

Academic / Other · 13 registered clinical trials — 4 currently recruiting.

StatusTrialPhaseStarted
RecruitingPatient Preference for Subcutaneous vs. Intravenous Immune Therapy
Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma
Phase 22025-11-04
RecruitingTebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
Uveal Melanoma
Phase 22025-08-18
WithdrawnPembrolizumab/Lenvatinib With and Without Healthy Donor FMT (hdFMT) in Relapsed/ Refractory (R/R) Melanoma
PD-1 Refractory Advanced Melanoma
Phase 22025-03-11
RecruitingHealthy-donor Microbiome MTP-101-C in Steroid Relapse/Refractory Immune-related Cutaneous Adverse Events (irCA
Immune-mediated Colitis (IMC), Immune-related Dermatitis
Phase 22025-01-23
RecruitingStudy of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC
Non Small Cell Lung Cancer
Phase 22025-01-08
Active Not RecruitingZimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
Melanoma
Phase 22022-03-16
CompletedPixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab
NSCLC, Metastatic Colorectal Carcinoma, Refractory Melanoma
Phase 22021-12-09
Active Not RecruitingNeoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)
Squamous Cell Carcinoma
Phase 22021-05-11
CompletedStudy of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab
Melanoma
Phase 22020-09-02
Active Not RecruitingNeoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD
Melanoma Stage III, Melanoma Stage IV
Phase 22020-06-12
CompletedCMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Diseas
Melanoma, Lymph Node Cancer
Phase 22018-08-08
CompletedNeoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma
Melanoma
Phase 12013-05-21
CompletedImmunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma
Melanoma
EARLY_Phase 12009-12-01